Dextromethorphan hydrobromide transdermal patch

A technology of dextromethorphan hydrobromide and transdermal patch, applied in the direction of medical preparations of non-active ingredients, organic active ingredients, organic non-active ingredients, etc. To achieve the effect of reducing side effects, reducing the total intake of drugs, and flexibly adjusting the dosage of drugs

Pending Publication Date: 2021-02-19
北京茗泽中和药物研究有限公司
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

When continuous antitussive is required, more oral administration dru

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0013] Dextromethorphan Hydrobromide 2%

[0014] The total amount of penetration enhancer is 1%, and the weight ratio of propylene glycol, myristic acid and menthone is 1:0.2:0.1; the rest of the polysiloxane pressure-sensitive adhesive matrix,

[0015] The preparation method is as follows

[0016] 1) Mix propylene glycol, myristic acid, menthone, dextromethorphan hydrobromide and polysiloxane pressure-sensitive adhesive matrix evenly, apply on the release layer, dry at 65-85°C, and then apply to the backing layer Composite, cut into patches, that is.

Embodiment 2

[0018] Dextromethorphan Hydrobromide 3%

[0019] The total amount of penetration enhancer is 2%, and the weight ratio of propylene glycol, myristic acid and menthone is 1:0.4:0.2; the rest of the polysiloxane pressure-sensitive adhesive matrix,

[0020] The preparation method is as follows

[0021] 1) Mix propylene glycol, myristic acid, menthone, dextromethorphan hydrobromide and polysiloxane pressure-sensitive adhesive matrix evenly, apply on the release layer, dry at 65-85°C, and then apply to the backing layer Composite, cut into patches, that is.

Embodiment 3

[0023] Dextromethorphan Hydrobromide 4%

[0024] The total amount of penetration enhancer is 3%, and the weight ratio of propylene glycol, myristic acid and menthone is 1:0.2:0.15; the rest of the polysiloxane pressure-sensitive adhesive matrix,

[0025] The preparation method is as follows

[0026] 1) Mix propylene glycol, myristic acid, menthone, dextromethorphan hydrobromide and polysiloxane pressure-sensitive adhesive matrix evenly, apply on the release layer, dry at 65-85°C, and then apply to the backing layer Composite, cut into patches, that is.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
Thicknessaaaaaaaaaa
Login to view more

Abstract

A dextromethorphan hydrobromide transdermal patch comprises a medicine carrying layer, a backing layer and an anti-sticking layer, and the medicine carrying layer is composed of dextromethorphan hydrobromide, a penetration enhancer and a pressure-sensitive adhesive matrix, and the weight percentage content of dextromethorphan hydrobromide in the medicine carrying layer is 2%-4%. The weight percentage of the penetration enhancer in the medicine carrying layer is 1%-3%, and the penetration enhancer is propylene glycol, myristic acid and menthone in the weight ratio of 1: (0.2-0.4): (0.1-0.2), wherein the pressure-sensitive adhesive matrix is a polysiloxane pressure-sensitive adhesive matrix.

Description

technical field [0001] The invention relates to a transdermal administration preparation, in particular to a transdermal patch with dextromethorphan hydrobromide as an active ingredient. Background technique [0002] Dextromethorphan Hydrobromid is a central antitussive drug that mainly inhibits the cough center of the medulla oblongata, and its effect is equivalent to that of codeine, but it has no analgesic and sedative effects of codeine, and has no addiction The therapeutic dose will not inhibit the secretion of the respiratory center and respiratory mucosa. In clinical application, the antitussive effect is remarkable, the incidence of adverse reactions is low, and the clinical application is extremely safe. It has the advantages of less dosage and good antitussive effect, and is more and more widely used in antitussive treatment. The specification of the existing dextromethorphan hydrobromide tablet is 15 mg. However, the biological half-life of oral administration i...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K9/70A61K31/485A61K47/08A61K47/10A61K47/12A61K47/34A61P11/14
CPCA61K9/7069A61K31/485A61K47/08A61K47/10A61K47/12A61P11/14
Inventor 李斐菲杨红伟姚永波
Owner 北京茗泽中和药物研究有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap